30 related articles for article (PubMed ID: 31482225)
1. Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.
Vasileiadis T; Chrisofos M; Safioleas M; Kontzoglou K; Papazisis K; Sdrolia A
BMC Cancer; 2019 Apr; 19(1):407. PubMed ID: 31039771
[TBL] [Abstract][Full Text] [Related]
2. Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A; Uemura M; Kato T; Ujike T; Nagahara A; Fujita K; Imamura R; Yamanaka Y; Tomiyama E; Tanigawa G; Miyagawa Y; Yoshioka T; Miyake O; Nonomura N
Int J Clin Oncol; 2019 Jan; 24(1):78-86. PubMed ID: 30094693
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance and Expression Pattern of RIP5 and VGLL4 in Clear Cell Renal Cell Carcinoma Patients Treated with Sunitinib.
Tomić T; Tomić D; Vukoja M; Kraljević M; Ljevak I; Glamočlija U; Tomić V; Vukojević K; Beljan Perak R; Šoljić V
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255254
[TBL] [Abstract][Full Text] [Related]
4. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
Br J Cancer; 2024 May; ():. PubMed ID: 38822145
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
Tomita Y; Tatsugami K; Nakaigawa N; Osawa T; Oya M; Kanayama H; Nakayama Kondoh C; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Tanaka S; Kimura A; Tamada S
Int J Urol; 2020 Nov; 27(11):952-959. PubMed ID: 32789967
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review.
Demlová R; Turjap M; Peš O; Kostolanská K; Juřica J
Ther Drug Monit; 2020 Feb; 42(1):20-32. PubMed ID: 31259881
[TBL] [Abstract][Full Text] [Related]
8. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
10. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
12. Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma.
Ishiyama R; Ishihara H; Kondo T; Takagi T; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
In Vivo; 2019; 33(6):2153-2160. PubMed ID: 31662551
[TBL] [Abstract][Full Text] [Related]
13. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma.
Yamada Y; Ohno Y; Kato Y; Kobayashi R; Hayashi H; Miyahara S; Nakane K; Mizutani K; Yokoi S; Fujii H; Iihara H; Ishihara T; Deguchi T; Sugiyama T; Suzuki A
Cancer Chemother Pharmacol; 2019 Nov; 84(5):987-992. PubMed ID: 31482225
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
